Mrs. Sheng-Chi Hsu , Department of Laboratory Medicaine, Chang Gung Memorial Hospital at LinKou , Taiwan
Sheng-Chi Hsu, M.S., is a leading expert in tumor biology, molecular pathology, and personalized medicine. Currently serving as the Deputy Director of the Department of Laboratory Medicine at Chang Gung Memorial Hospital, Linkou Branch, he has extensive experience in cancer diagnostics, molecular pathology, and clinical research. With a strong academic background and a commitment to advancing medical science, Hsu has contributed significantly to the field of oncology, focusing on novel diagnostic approaches and precision medicine strategies. His research has resulted in several impactful publications, enhancing diagnostic accuracy and the development of targeted therapies for various cancers. Hsu’s work has played a pivotal role in improving patient outcomes and shaping the future of cancer treatment in Taiwan.
Publication Profile:
Scopus
Strengths for the Award:
Sheng-Chi Hsu has demonstrated exceptional expertise in tumor biology, molecular pathology, and personalized medicine, contributing to groundbreaking advancements in cancer diagnostics and precision medicine. His leadership roles at Chang Gung Memorial Hospital, particularly in the Department of Laboratory Medicine and Pathology, showcase his ability to manage large teams and oversee complex laboratory operations while pushing the boundaries of research. His publications in prestigious journals highlight significant research achievements, including the identification of key biomarkers for cancer therapies and advancing molecular diagnostic techniques. Hsu’s research on cancer biomarkers, including ALK translocation and ROS1 translocation in non-small cell lung cancer (NSCLC), has provided valuable insights into targeted therapies, which are directly influencing patient care and therapeutic approaches. His work on multidrug resistance also opens new therapeutic avenues to overcome chemotherapy resistance, making his contributions pivotal to modern cancer treatment strategies.
Areas for Improvements:
While Hsu’s research accomplishments are impressive, expanding his involvement in large-scale, multi-center clinical trials could further enhance the real-world application and validation of his research findings. Collaborating with international institutions or expanding his research scope to include more diverse populations may also increase the generalizability and impact of his findings. Additionally, although Hsu has an extensive background in molecular diagnostics, there may be room to explore emerging technologies, such as artificial intelligence in pathology, to further optimize diagnostic procedures and improve precision medicine outcomes.
Experience:
Sheng-Chi Hsu has over 15 years of experience in laboratory medicine and pathology, with expertise in tumor pathology and molecular diagnostics. He is currently the Deputy Director of the Department of Laboratory Medicine at Chang Gung Memorial Hospital, where he leads research and development in laboratory diagnostics. Previously, he served as the Deputy Director of the Department of Pathology, overseeing innovations in histopathological diagnostics. Hsu’s leadership has been instrumental in advancing cancer diagnostics, optimizing molecular diagnostic techniques, and improving laboratory workflows. His career also includes roles as a Chief and Senior Medical Technologist, where he pioneered research in tumor pathology, focusing on biomarker identification and the development of diagnostic assays.
Research Focus:
Sheng-Chi Hsu’s research focuses on advancing molecular diagnostics, particularly in oncology. His work aims to enhance diagnostic precision for various cancers, with a strong emphasis on personalized medicine. Hsu has made significant contributions to the genetic characterization of tumors, identifying key biomarkers for targeted therapies in non-small cell lung cancer (NSCLC), synovial sarcoma, and gestational trophoblastic disease. His research in multidrug resistance mechanisms and the role of Wnt5A in cancer therapy has opened new avenues for overcoming chemoresistance. Hsu’s pioneering studies in molecular pathology have significantly impacted clinical practices, helping improve treatment strategies and patient outcomes through advanced diagnostics.
Publications Top Notes:
- Wang HS, Liu CY, Hsu SC, Huang SC, Hung TH, Ng KF, Chen TC. A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan. Int J Mol Sci. 2022 May 21;23(10):5789. 📄
- Hsu SC, Hung TH, Wang CW, Ng KF, Chen TC. Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer. Pathol Int. 2015 May;65(5):231-9. 📄
- Hung TH, Hsu SC, Cheng CY, Choo KB, Tseng CP, Chen TC, Lan YW, Huang TT, Lai HC, Chen CM, Chong KY. Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway. Oncotarget. 2014 Dec 15;5(23):12273-90. 📄
- Chen KH, Hsu SC, Chen HY, Ng KF, Chen TC. Utility of fluorescence in situ hybridization for ploidy and p57 immunostaining in discriminating hydatidiform moles. Biochem Biophys Res Commun. 2014 Apr 4;446(2):555-60. 📄
- Chuang HC, Hsu SC, Huang CG, Hsueh S, Ng KF, Chen TC. Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma. Pathol Int. 2013 Dec;63(12):573-80. 📄
Conclusion:
Sheng-Chi Hsu is highly deserving of the “Best Researcher Award” due to his outstanding contributions to cancer research and diagnostic advancements. His innovative approach to tumor pathology and molecular diagnostics, along with his leadership in clinical and research operations, makes him a transformative figure in the field. With a continued focus on expanding his research scope and incorporating emerging technologies, Hsu’s impact on personalized cancer treatments is poised to grow even further.